What it is
CJC-1295 + ipamorelin is not a single compound. It is a pairing of two peptides that act on the growth hormone axis through different doors, sold either as two separate vials or pre-mixed in one.
- CJC-1295, in this context almost always the no-DAC version, also called Modified GRF (1-29). It is a GHRH analogue: a copy of the hypothalamic signal that tells the pituitary to release GH, with four amino acid swaps to slow its breakdown.
- Ipamorelin is a five amino acid ghrelin mimetic. It triggers GH release through the ghrelin receptor.
It is one of the most common GH peptide products in the Philippine research market, and the page name on this site reflects how people search for it. There is, however, no published human protocol for the combination, and this page does not describe one.
Why pair a GHRH analogue with a ghrelin mimetic
The pituitary somatotroph, the cell that makes growth hormone, has two separate stimulating inputs.
- The GHRH receptor. GHRH is the main "release" signal from the hypothalamus. CJC-1295, sermorelin and tesamorelin all act here.
- The ghrelin receptor (GHS-R1a). Ghrelin, and synthetic mimics such as ipamorelin, GHRP-6 and MK-677, act through a different receptor and signalling pathway. In the 1998 animal work, GHRH antagonists and GHRP antagonists showed that ipamorelin works through the GHRP-type receptor, not the GHRH one.
Because the two inputs are separate, stimulating both at once can do more than either alone. That was shown decades ago: Bowers and colleagues (1990) gave 18 healthy men a GH-releasing peptide (the hexapeptide now called GHRP-6), GHRH, or both by IV injection. Low doses of the peptide combined with GHRH released GH synergistically, meaning more than the sum of each alone.
That is the whole scientific rationale for the pairing. It is a sound physiological idea. It is also a finding about a different peptide (GHRP-6, not ipamorelin) and a different GHRH (the natural 44 amino acid hormone, not CJC-1295), given intravenously in a single session.
Why these two in particular
The choice of ipamorelin over GHRP-6 or GHRP-2 comes from its selectivity. In pigs, GHRP-6 and GHRP-2 raised ACTH and cortisol, while ipamorelin did not, even at doses over 200 times what was needed for GH release. That has not been confirmed in a human controlled trial.
The choice of the no-DAC CJC-1295 over the DAC version comes from timing. Ipamorelin gives a single GH pulse: in healthy men the peak came at about 40 minutes after an IV infusion and GH then fell back to negligible levels, with a drug half-life of about 2 hours. A short-acting GHRH analogue matches that pulse. CJC-1295 with DAC instead holds GH and IGF-1 up for days, which changes the pattern entirely.
What the research found
The combination: no published human or animal trial of CJC-1295 plus ipamorelin that we could find.
The components:
| Human evidence | Animal evidence | |
|---|---|---|
| CJC-1295 no DAC | None published | Structure described in the 2005 CJC-1295 rat study |
| CJC-1295 with DAC | Two 2006 trials in healthy adults; GH raised for 6 days or more | Rats |
| Ipamorelin | PK study in healthy men (1999); Phase 2 surgery trial, no benefit (2014) | Rats, pigs |
Everything claimed for the pair beyond "it raises GH" is extrapolation from these pieces.
Side effects reported in studies
There is no study of the combination, so no combination side-effect profile exists. For each component, see its own page. The US FDA has raised compounding safety concerns about both: for CJC-1295, possible immunogenicity and serious adverse events including increased heart rate and a systemic vasodilatory reaction; for ipamorelin, poor characterisation, minimal toxicology data, and possible effects on fertility and fetal development.
Both raise IGF-1. The general concerns about raised IGF-1 apply: fluid retention, joint aches, reduced insulin sensitivity, and the open question of IGF-1 and cancer risk.
Pre-mixed vial vs separate vials
A pre-mixed vial fixes the ratio of the two peptides, so neither can be adjusted or stopped on its own. Separate vials allow each to be handled independently, at the cost of two reconstitutions. Either way, the label should say which CJC-1295 version is inside.
Status in the Philippines
Neither CJC-1295 nor ipamorelin is registered with FDA Philippines, and neither has been approved as a medicine in any country. Neither is a controlled substance under RA 9165. The pair is sold locally through research-chemical suppliers. IGF-1, the marker every GH-axis study tracks, can be tested at Philippine laboratories; see bloodwork in the Philippines.
Local stock CJC-1295 + Ipamorelin 10mg at Primara Labs, delivered in Metro Manila and nationwide. Research use only.
Storage
Keep the freeze-dried powder refrigerated. After mixing with bacteriostatic water, store at 2 to 8°C, away from the freezer and the door. Plan for brownouts with a cooler and ice packs. The CJC-1295 calculator and ipamorelin calculator handle reconstitution arithmetic.
